Why the study?
Does primary adjunctive corticosteroid therapy improve outcomes in patients with Kawasaki disease with coronary artery aneurysms at diagnosis?
Does primary adjunctive corticosteroid therapy improve outcomes in patients with Kawasaki disease with coronary artery aneurysms at diagnosis?
Primary adjunctive corticosteroid therapy may improve treatment response and promote coronary artery aneurysm regression in patients with Kawasaki disease presenting with aneurysms.
Answers are grounded in this paper and cite their sources.
May support adjunctive corticosteroids in Kawasaki disease with aneurysms; leaves open need for randomized confirmation before practice change.
Primary adjunctive corticosteroid therapy is associated with decreased initial treatment resistance, greater improvement in inflammatory markers and higher likelihood of CAA regression in patients who have CAA at diagnosis. Multi-centre, randomised controlled trials are needed to confirm the benefits of corticosteroids in patients with CAA at diagnosis and to compare corticosteroids with other adjunctive therapies.
No takes yet. Share an insight, caveat, or question.
Friedman et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: